SCHEMBL2193074

SCHEMBL2193074

O=P(O)(O)Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.60
CYP1A1 P04798 5/20 0.60
CYP1B1 Q16678 4/20 0.60
TTR P02766 3/20 0.60
ALOX5 P09917 3/20 0.60
CISD1 Q9NZ45 2/20 0.59
KDM4E B2RXH2 5/20 0.58
MEN1 O00255 4/20 0.58
MAPT P10636 4/20 0.58
KMT2A Q03164 4/20 0.58
PTGS1 P23219 4/20 0.58
CYP1A2 P05177 3/20 0.58
ALDH1A1 P00352 3/20 0.58
TP53 P04637 3/20 0.58
CYP3A4 P08684 3/20 0.58
HPGD P15428 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HSD17B10 Q99714 3/20 0.58
LMNA P02545 3/20 0.58
CYP19A1 P11511 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340348 1.00 PTGS2 (0.60) PTGS2CYP1A1CYP1B1TTRALOX5
SCHEMBL4166639 0.98 PTGS2 (0.58) PTGS2CYP1A1CYP1B1TTRALOX5
SCHEMBL2763623 0.88 PTGS2 (0.54) PTGS2CYP1A1CYP1B1TTRALOX5
SCHEMBL30340032 0.86 PTGS1 (0.58) PTGS2CYP1A1CYP1B1TTRALOX5
SCHEMBL6951492 0.86 KDM4E (0.50) PTGS2CYP1A1CYP1B1TTRALOX5
SCHEMBL741474 0.84 INPPL1 (0.59) PTGS2CYP1A1CYP1B1TTRALOX5
Resveratrol SCHEMBL27678698 0.82 PTGS1 (0.79) PTGS2CYP1A1CYP1B1TTRALOX5
SCHEMBL4454764 0.78 INPPL1 (0.71) CA1CA2BLMINPPL1INPP5A
SCHEMBL25194538 0.77 CYP3A4 (0.68) MEN1MAPTKMT2ACYP1A2TP53
SCHEMBL4736118 0.75 CYP1A1 (0.66) PTGS2CYP1A1CYP1B1TTRALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11622920-B2 Delivery system for active agents SYMRISE AG (DE) 2023-04-11 US claimed
EP-3383354-B1 DELIVERY SYSTEM FOR ACTIVE AGENTS SYMRISE AG (DE) 2023-03-22 EP claimed
EP-3081207-B1 USE OF A LIPOSOME COMPOSITION SYMRISE AG (DE) 2022-09-21 EP claimed
US-20180353392-A1 DELIVERY SYSTEM FOR ACTIVE AGENTS SYMRISE AG (DE) 2018-12-13 US claimed
EP-3383354-A1 DELIVERY SYSTEM FOR ACTIVE AGENTS Symrise AG (DE) 2018-10-10 EP claimed
CN-108366933-A Active agent delivery system 西姆莱斯股份公司 2018-08-03 CN claimed
WO-2017092818-A1 DELIVERY SYSTEM FOR ACTIVE AGENTS SYMRISE AG (DE) 2017-06-08 WO claimed
WO-2016166038-A1 WHITENING COMPOSITIONS SYMRISE AG (DE) 2016-10-20 WO claimed
EP-3081207-A1 WHITENING COMPOSITIONS Symrise AG (DE) 2016-10-19 EP claimed
US-8465973-B2 Topical compositions containing phosphorylated polyphenols ESTEE LAUDER COORDINATION CENTER N.V. (BE) 2013-06-18 US claimed
US-20090035236-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent ELC MANAGEMENT LLC 2009-02-05 US claimed
US-11622920-B2 Delivery system for active agents SYMRISE AG (DE) 2023-04-11 US disclosed
EP-3383354-B1 DELIVERY SYSTEM FOR ACTIVE AGENTS SYMRISE AG (DE) 2023-03-22 EP disclosed
CN-109481422-B Graphene oxide electrothermal film transdermal patch 广西中医药大学 2022-11-11 CN disclosed
EP-3081207-B1 USE OF A LIPOSOME COMPOSITION SYMRISE AG (DE) 2022-09-21 EP disclosed
US-20090247490-A1 Topical Compositions Containing Phosphorylated Polyphenols DECLERCQ LIEVE 2009-10-01 US disclosed
WO-2009105294-A2 TOPICAL COMPOSITIONS AND METHODS FOR WHITENING SKIN ELC MANAGEMENT LLC (US) 2009-08-27 WO disclosed
US-20080095866-A1 delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning it to its native active form AJINOMOTO OMNICHEM S.A. (BE) 2008-04-24 US disclosed
EP-1799228-A1 TOPICAL COMPOSITIONS CONTAINING PHOSPHORYLATED POLYPHENOLS Ajinomoto Omnichem S.A. (BE) 2007-06-27 EP disclosed
WO-2006029484-A1 TOPICAL COMPOSITIONS CONTAINING PHOSPHORYLATED POLYPHENOLS AJINOMOTO OMNICHEM S.A. (BE) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247490-A1 Topical Compositions Containing Phosphorylated Polyphenols PPP5C, CHAMP1, PLK1 PTGS2 4023/4885CYP1A1 2169/4885CYP1B1 2766/4885
US-20090035236-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent CUTA, LRAT, RARA PTGS2 2396/4885CYP1A1 1737/4885CYP1B1 1935/4885
US-20080095866-A1 delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning it to its native active form KRT18, DUSP6, PPP5C PTGS2 3776/4885CYP1A1 836/4885CYP1B1 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.